Hospital
District Hospital Holdings INC
District Hospital Holdings INC was paid $9.44M by Medicaid between Jan 2018 and Dec 2024, across 150 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoDISTRICT HOSPITAL HOLDINGS INC
BELLE GLADE, FL 33430
BELLE GLADE, FL 33430
33aNPI1801885413assigned 10/17/2005
33bProvider typeRural Acute Care Hospital
28Total paid$9.44M
24GClaims415,661
24DCodes billed150
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAVIS, DARCY controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,444 | $669K | |
| 2019 | 96,760 | $818K | |
| 2020 | 63,996 | $619K | |
| 2021 | 65,967 | $1.31M | |
| 2022 | 74,828 | $2.38M | |
| 2023 | 54,555 | $2.19M | |
| 2024incomplete | 34,111 | $1.45M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 20,542 | 17,640 | $2.32M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 21,622 | 19,068 | $2.02M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 11,435 | 8,353 | $1.52M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.9% | 9,029 | 7,022 | $654K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 1,993 | 1,699 | $492K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 4,143 | 3,411 | $375K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 5,066 | 4,074 | $199K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 1,030 | 820 | $165K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 2,191 | 1,922 | $140K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 1,637 | 1,373 | $109K |
| 80053 | Comprehensive metabolic panel | 1.1% | 22,475 | 15,822 | $102K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,340 | 7,844 | $85K |
138 more codes
| G0378 | Hospital observation service, per hour | <1% | 9,070 | $83K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,239 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,868 | $59K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,576 | $59K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,011 | $54K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,457 | $54K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,371 | $47K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,039 | $40K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,349 | $38K |
| 84484 | <1% | 7,805 | $38K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,209 | $35K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,894 | $33K |
| 82948 | <1% | 7,273 | $33K | |
| 85027 | <1% | 3,753 | $33K | |
| 85007 | <1% | 2,790 | $27K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,057 | $26K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,710 | $24K |
| 83690 | <1% | 7,271 | $24K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 25,030 | $24K |
| 96376 | <1% | 4,053 | $23K | |
| 94760 | <1% | 3,780 | $23K | |
| 85730 | <1% | 4,715 | $22K | |
| 85610 | <1% | 4,893 | $22K | |
| 76801 | <1% | 1,067 | $21K | |
| 81001 | <1% | 13,018 | $21K | |
| 87040 | <1% | 4,520 | $20K | |
| 81025 | <1% | 11,380 | $19K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 356 | $14K |
| 82550 | <1% | 3,884 | $14K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,591 | $13K |
| 83735 | <1% | 4,012 | $12K | |
| 81003 | <1% | 4,683 | $11K | |
| 83880 | <1% | 1,786 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,702 | $11K |
| 83605 | <1% | 2,036 | $11K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 292 | $11K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,369 | $10K |
| 59025 | Fetal non-stress test | <1% | 397 | $10K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 410 | $9K |
| 87077 | <1% | 2,150 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,630 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,640 | $6K |
| A9270 | Non-covered item or service | <1% | 1,955 | $6K |
| 87430 | <1% | 2,136 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,292 | $5K |
| 94664 | <1% | 526 | $5K | |
| 87186 | <1% | 1,638 | $5K | |
| 87807 | <1% | 4,675 | $5K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 605 | $5K |
| 87088 | <1% | 4,456 | $5K | |
| 93976 | <1% | 131 | $5K | |
| 73562 | <1% | 798 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 412 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 33 | $4K |
| 86901 | <1% | 1,741 | $4K | |
| 93971 | <1% | 191 | $4K | |
| 86140 | <1% | 1,803 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 302 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 11,767 | $3K |
| 85378 | <1% | 775 | $3K | |
| 73630 | <1% | 412 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 655 | $3K |
| J1815 | Injection, insulin, per 5 units | <1% | 374 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 528 | $3K |
| 73610 | <1% | 310 | $3K | |
| 84702 | <1% | 2,581 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 215 | $3K |
| 84703 | <1% | 607 | $2K | |
| 74018 | <1% | 529 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 693 | $2K |
| 10060 | <1% | 17 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,838 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 650 | $1K |
| 86900 | <1% | 927 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 322 | $1K |
| 96367 | <1% | 336 | $1K | |
| 76770 | <1% | 12 | $1K | |
| 86850 | <1% | 471 | $1K | |
| 76641 | <1% | 13 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 50 | $1K |
| 94010 | <1% | 30 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 121 | $1K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 20 | $1K |
| 73030 | <1% | 162 | $1K | |
| 80061 | Lipid panel | <1% | 348 | $803.20 |
| 87070 | <1% | 1,602 | $774.06 | |
| 85379 | <1% | 498 | $697.95 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 25 | $690.05 |
| 87081 | <1% | 1,898 | $684.92 | |
| 73130 | <1% | 174 | $673.95 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 654 | $639.96 |
| 87210 | <1% | 377 | $639.17 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 228 | $631.28 |
| 82728 | <1% | 198 | $599.21 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 33 | $506.10 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,140 | $483.25 |
| 82803 | <1% | 224 | $413.61 | |
| 72100 | <1% | 119 | $344.83 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 145 | $288.53 |
| 80076 | <1% | 479 | $261.50 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 49 | $256.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 143 | $253.47 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 13 | $244.15 |
| 83615 | <1% | 131 | $219.58 | |
| 82150 | <1% | 203 | $213.43 | |
| 93970 | <1% | 18 | $178.68 | |
| 86403 | <1% | 69 | $176.48 | |
| 84439 | <1% | 168 | $157.39 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 368 | $126.75 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 284 | $113.96 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 697 | $99.93 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 234 | $96.60 |
| 73590 | <1% | 13 | $59.81 | |
| 86706 | <1% | 20 | $58.60 | |
| 73502 | <1% | 14 | $50.36 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 155 | $28.77 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 216 | $28.20 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 64 | $20.16 |
| 80074 | <1% | 19 | $19.83 | |
| 84550 | <1% | 17 | $8.01 | |
| 85651 | <1% | 14 | $7.88 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 19 | $5.34 |
| 86592 | <1% | 32 | $5.10 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 488 | $3.08 |
| 73080 | <1% | 14 | $1.78 | |
| 82270 | <1% | 13 | $1.54 | |
| 87581 | 0% | 14 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 16 | $0.00 |
| 87486 | 0% | 14 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 14 | $0.00 |
| 94761 | 0% | 19 | $0.00 | |
| 80143 | 0% | 16 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 14 | $0.00 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 110 | $0.00 |
| 84100 | 0% | 34 | $0.00 | |
| 73110 | 0% | 14 | $0.00 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 17 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIS, DARCY (CEO)
| Provider | Location | Paid |
|---|---|---|
| District Clinic Holdings INC | Lantana, FL | $3.01M |
| District Clinic Holdings, INC. | West Palm Beach, FL | $2.58M |
| District Clinic Holdings INC | West Palm Beach, FL | $1.49M |
| District Clinic Holdings INC | Lake Worth, FL | $576K |
| District Clinic Holdings INC | Delray Beach, FL | $355K |
| District Clinic Holdings INC | Belle Glade, FL | $341K |
| Health Care District of Palm Beach County | West Palm Beach, FL | $209K |
| Health Care District of Palm Beach County | West Palm Beach, FL | $117K |
| District Clinic Holdings INC | Jupiter, FL | $79K |
| District Clinic Holdings INC | Boca Raton, FL | $76K |
| District Clinic Holdings INC | West Palm Beach, FL | $40K |
| District Clinic Holdings INC | Belle Glade, FL | $36K |
| District Clinic Holdings INC | West Palm Beach, FL | $4K |
| Health Care District of Palm Beach County | Riviera Beach, FL | $2K |
| Charles a Wardle | Longview, WA | $552.46 |
| Health Care District of Palm Beach County | Riviera Beach, FL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.